BridgeMD
Intra-operative evaluation of a novel FLUorescENt C-nnEt tracer in penile and tongue cancer
EU CTIS ID: 2024-518046-25-00
What this study is testing
The feasibility of intraoperative visualization of primary penile and tongue tumours using c-Met-based receptor-mediated fluorescence imaging.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Written informed consent, prior to performing any protocol related procedures.
- Age ≥ 18 years at time of study entry.
- ≥ T1 penile or tongue squamous cell cancer
- Scheduled for surgical primary tumour resection
You likely can't join if
- Involvement in the planning and/or conduct of the study.
- Pregnant woman
- Abstaining from usage of two forms of barrier contraceptive or actively planning pregnancy within 90 days.
- Severe kidney insufficiency
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.